The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's popular obesity drug Wegovy. The U.S. Food and Drug Administration's approval was based on data from a late-stage study,

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,